CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞治疗实体瘤的临床研究
英文原题：Clinical Investigations of CAR-T Cell Therapy for Solid Tumors.
查看英文原题
Clinical Investigations of CAR-T Cell Therapy for Solid Tumors.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
细胞疗法是一种卓越的靶向免疫疗法，在癌症治疗的新时代具有治疗实体瘤的巨大潜力。细胞治疗产品包括基因工程化细胞产品和非基因工程化细胞产品。近期已有几种细胞疗法，尤其是嵌合抗原受体（CAR）-T细胞疗法，被批准为癌症的新型治疗策略。许多针对实体瘤的细胞疗法临床试验，以单纯细胞疗法或与其他治疗联合的形式，已经开展或正在进行中。然而，仍然存在挑战，因为也观察到了细胞疗法的不良事件和有限疗效。在此，我们简要总结了已开展和正在进行的细胞疗法临床试验的临床里程碑，介绍了CAR的演变，以CAR-T 为主要焦点讨论了这些治疗模式的挑战和局限性，并分析了不同国家监管政策的差异。
展开英文摘要原文
Cell therapy is a distinguished targeted immunotherapy with great potential to treat solid tumors in the new era of cancer treatment. Cell therapy products include genetically engineered cell products and non-genetically engineered cell products.
Several recent cell therapies, especially chimeric antigen receptor (CAR)-T cell therapies, have been approved as novel treatment strategies for cancer. Many clinical trials on cell therapies, in the form of cell therapy alone or in combination with other treatments, in solid tumors, have been conducted or ongoing.
However, there are still challenges since adverse events and the limited efficacy of cell therapies have also been observed.
Here, we concisely summarize the clinical milestones of the conducted and ongoing clinical trials of cell therapy, introduce the evolution of CARs, discuss the challenges and limitations of these therapeutic modalities taking CAR-T as the main focus, and analyze the disparities in the regulatory policies in different countries.
论文信息
- 作者
- Chen K、Wang S、Qi D、Ma P、Fang Y、Jiang N、Wu E、Li N
- 第一作者单位
- National Health Commission (NHC) Key Laboratory of Pulmonary Immune-Related Diseases, Guizhou Provincial People's Hospital, Guiyang, China.China
- 通讯作者单位
- Clinical Cancer Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.China
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Frontiers in immunology2022
- 原文标识
- PubMed 35924243 · DOI 10.3389/fimmu.2022.896685
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →